4.4 Review

Personalised medicine for multiple sclerosis care

期刊

MULTIPLE SCLEROSIS JOURNAL
卷 23, 期 3, 页码 362-369

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1352458516672017

关键词

Treatment response; outcome measurement; multiple sclerosis

资金

  1. Imperial College Healthcare Trust Biomedical Research Centre
  2. MRC [MR/N026934/1, MC_PC_17114, UKDRI-5003] Funding Source: UKRI
  3. Medical Research Council [UKDRI-5003, MC_PC_17114, MR/N026934/1, MR/K501013/1] Funding Source: researchfish
  4. National Institute for Health Research [NF-SI-0514-10022] Funding Source: researchfish

向作者/读者索取更多资源

Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据